AnTolRx, Inc.
Industry
- Pharmaceuticals
- Biotechnology
- Nanotechnology, Chips, etc.
Latest on AnTolRx, Inc.
Financings Third-quarter 2016 biopharma financing totaled $7.4 billion, a 54% increase over Q2’s $4.8 billion. Follow-on public offerings were again the lead financing vehicle, bringing in $3.36 billi
IN VITRO DIAGNOSTICS Mergers & Acquisitions Alere Inc. TechLab Inc. Pharos Capital Group has taken a controlling interest in TechLab Inc. from Alere Inc. and TechLab's founders Dr. Tracy Wilki
Advantagene Closes $14.2m Series A Round Immuno-oncology firm Advantagene Inc. raised $14.2m through the sale of its Series A convertible preferred shares to undisclosed investors. National Securi
Biopharma start-ups brought in half as much funding in the third quarter as in the second quarter, but the number of alliances for new and emerging therapeutics firms stayed the same. Big pharma made